COREG CR (carvedilol phosphate) by Viatris is β-adrenoreceptor blocking activity is present in the s(-) enantiomer and α 1 -adrenergic blocking activity is present in both r(+) and s(-) enantiomers at equal potency. First approved in 2006.
Drug data last refreshed 11h ago · AI intelligence enriched 17h ago
COREG CR is an extended-release oral capsule formulation of carvedilol phosphate, a non-selective beta-blocker with alpha-1 blocking activity used primarily for heart failure and hypertension. The S(-) enantiomer provides beta-blocking effects while both enantiomers contribute alpha-1 blocking activity, resulting in vasodilation and reduced cardiac workload. Carvedilol has no intrinsic sympathomimetic activity, making it a pure antagonist.
Post-LOE product with minimal Part D utilization signals consolidation and reduced commercial team investment; career focus shifts to retention rather than growth.
β-adrenoreceptor blocking activity is present in the S(-) enantiomer and α 1 -adrenergic blocking activity is present in both R(+) and S(-) enantiomers at equal potency. Carvedilol has no intrinsic sympathomimetic activity.
Indication data is being enriched from DailyMed and FDA labeling. Check back soon for approved therapeutic uses.
Study to Examine the Effect of Food on the Pharmacokinetics of the Fixed Dose Combination of COREG CR and Lisinopril.
Efficacy of Coreg CR and Lisinopril on Markers for Cardiovascular Functional and Structural Disease
Study to Investigate Dose Proportionality of the Fixed Dose Combination of COREG CR and Lisinopril.
Study to Demonstrate the Bioequivalence of the Fixed Dose Combination of COREG CR™ and Lisinopril to Its Components
A Study to Compare COREG CR to COREG CR Fixed-dose Combination in Patients With High Blood Pressure
Worked on COREG CR at Viatris? Share your interview experience or compensation data (+7 days Pro)
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.
Upgrade to Pro to access patent cliff timelines and LOE dates and other premium pharma intelligence.
Upgrade to Pro — $25/moUpgrade to Pro to access Medicare Part D spending data and other premium pharma intelligence.
Upgrade to Pro — $25/moPatent cliff in less than a year — expect lifecycle management and generic defense hiring
Working on COREG CR represents a consolidation/defensive career phase rather than growth opportunity; team size and investment are declining as LOE approaches. Professionals on this brand gain deep expertise in post-patent lifecycle management, generic transition strategies, and mature market dynamics—valuable for portfolio optimization roles.